Magnetic Resonance (MR) Imaging to Determine High Risk Areas in Patients With Malignant Gliomas and to Design Potential Radiation Plans and to Examine Metabolite Changes in Gliomas and Other Solid Tumors

StatusRecruiting
PhaseNot applicable
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 11 months later Sep 2026 → Sep 2027
See other at-risk trials from Memorial Sloan Kettering Cancer Center

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion pushed from Sep 2026 to Sep 2027
    • Primary endpoints: details revised at 1 of 1 entry
    • Eligibility criteria expanded, about 10 words
  2. Primary and study completion dates: Sep 2025 to Sep 2026v39
  3. Primary and study completion dates: Sep 2024 to Sep 2025v38
  4. Primary and study completion dates: Sep 2023 to Sep 2024v37
  5. Site contact updatedv36
Show 34 earlier versionsHide 34 earlier versions
  1. Re-verified, no change to tracked fieldsv35
  2. Primary and study completion dates: Sep 2021 to Sep 2023v34
  3. 2 versions Re-verified since Jun 23, 2020, no change to tracked fieldsv32-v33
  4. Enrollment target: 125 to 135v31
  5. Primary and study completion dates: Sep 2020 to Sep 2021v30
  6. Primary and study completion dates: Sep 2019 to Sep 2020v29
  7. Primary and study completion dates: Mar 2019 to Sep 2019v28
  8. Enrollment target: 190 to 125v27
  9. Primary and study completion dates: Mar 2018 to Mar 2019v26
  10. Enrollment target: 150 to 190v25
  11. Re-verified, no change to tracked fieldsv24
  12. Primary and study completion dates: Mar 2017 to Mar 2018v23
  13. Re-verified, no change to tracked fieldsv22
  14. Enrollment target: 100 to 150
    • Eligibility criteria expanded, about 8 words
    v21
  15. Primary and study completion dates: Mar 2016 to Mar 2017v20
  16. Re-verified, no change to tracked fieldsv19
  17. Primary and study completion dates: Mar 2015 to Mar 2016
    • Study site revised
    v18
  18. 2 versions Re-verified since Jun 3, 2014, no change to tracked fieldsv16-v17
  19. Eligibility criteria expanded, about 11 words
    • Study title expanded, about 11 words
    v15
  20. Primary and study completion dates: Mar 2014 to Mar 2015v14 Show 4 more changesShow less
    • Enrollment target: 76 to 100
    • Secondary endpoints revised (2)
    • Eligibility criteria expanded, about 2 words
    • Study title shortened, about 2 words
  21. Re-verified, no change to tracked fieldsv13
  22. Secondary endpoints: 1 to 2
    • Eligibility criteria expanded, about 2 words
    v12
  23. Primary and study completion dates: Mar 2013 to Mar 2014v11
  24. Re-verified, no change to tracked fieldsv10
  25. Primary and study completion dates: Mar 2012 to Mar 2013v9
  26. Re-verified, no change to tracked fieldsv8
  27. Primary and study completion dates: Mar 2011 to Mar 2012v7
  28. Enrollment target: 17 to 76v6
  29. Trial status: Active, Not Recruiting to Recruiting
    • Primary and study completion dates: Mar 2010 to Mar 2011
    • Site details revised
    v5
  30. Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 16 to confirmed 17
    • Primary and study completion dates: Mar 2011 to Mar 2010
    • Site details revised
    v4
  31. Re-verified, no change to tracked fieldsv3
  32. Secondary endpoints: details revised at 1 of 1 entryv2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The researchers think that the use of advanced MR imaging may help people with this disease, because it may better predict areas within a malignant glioma (brain tumor) that are at a high risk of recurring. WeThe reserchers are doing this study to see whether this advanced imaging is a safe treatment that causes few or mild side effects in people with brain tumors.
Trial Details
NCT Number NCT00870129
Lead Sponsor Memorial Sloan Kettering Cancer Center
Conditions
(from sponsor)		 Brain Cancer, Glioma
Related terms Brain Neoplasms, Glioma
Enrollment 135 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov